Synthetic Lethal Targeting of <i>ARID1A</i> -Mutant Ovarian Clear Cell Tumors with Dasatinib

Abstract excerpt

New targeted approaches to ovarian clear cell carcinomas (OCCC) are needed, given the limited treatment options in this disease and the poor response to standard chemotherapy. Using a series of high-throughput cell-based drug screens in OCCC tumor cell models, we have identified a synthetic lethal (SL) interaction between the kinase inhibitor dasatinib and a key driver in OCCC, ARID1A mutation. Imposing ARID1A...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer Mechanisms and Therapy
• Share to Chromatin Remodeling and Cancer
• Share to Protein Degradation and Inhibitors